Biotechs That Could Break from the Pack
Merrill Lynch's Eric Ende pinpoints four with accelerating earnings and improving fundamentals: Amgen, MedImmune, Gilead, and NPS
By Gene Marcial
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
You might like: